Compare · CDXC vs CGC
CDXC vs CGC
Side-by-side comparison of ChromaDex Corporation (CDXC) and Canopy Growth Corporation (CGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXC and CGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 16.2x CDXC ($176.9M).
- CGC has hit the wire 9 times in the past 4 weeks while CDXC has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 5 for CDXC).
- Company
- ChromaDex Corporation
- Canopy Growth Corporation
- Price
- $7.87-0.76%
- $0.71-3.03%
- Market cap
- $176.9M
- $2.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 9
- Recent ratings
- 5
- 19
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
Latest CGC
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form 8-K filed by Canopy Growth Corporation
- Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Director Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation
- Director Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability
- Director Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)
- Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
- SEC Form DEFA14A filed by Canopy Growth Corporation